Journal article
The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial
Abstract
AIMS: The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial demonstrated that rivaroxaban 2.5 mg BID with aspirin 100 mg was more effective than aspirin 100 mg daily alone for the prevention of cardiovascular (CV) death, stroke, or myocardial infarction in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD). We aimed to examine the cost-effectiveness of rivaroxaban using …
Authors
Lamy A; Eikelboom J; Tong W; Yuan F; Bangdiwala SI; Bosch J; Connolly S; Lonn E; Dagenais GR; Branch KRH
Journal
European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, No. 5, pp. 502–510
Publisher
Oxford University Press (OUP)
Publication Date
August 7, 2023
DOI
10.1093/ehjqcco/qcac054
ISSN
2058-5225